The increasing use of various technologies, screening examinations, genomic profiling, and cross-matching is making transplants a viable means of restoring an individual’s life. The growing CAGR of the transplant industry is responsible for the increased number of transplant surgeries in key nations. For example, in 2021 there were 41,354 organ transplants performed in the United States and 5,273 organ transplants performed in France. Conditions including tuberculosis, end-stage renal failure, and liver cirrhosis are prevalent in the elderly population, necessitating transplant surgery.
The American Transplant Foundation hosted the DLA Awards in 2022 as a fundraiser event to support initiatives that raise public awareness about organ donation and transplantation. An awareness campaign was carried out in 2021 by the Organ Receiving and Giving Awareness Network (India) with the goal of increasing public support for organ donation for transplant procedures in India.Long runs of three, five, and ten kilometers are held in the US to raise public awareness of organ transplantation and the importance of saving lives.
The annual number of organ donors and the amount of organ donations needed differ significantly. The main causes of the low yearly organ donation rate worldwide include inadequate medical reimbursement for living organ donors, stringent government regulations, and low public awareness of organ donation.
Specialized molecular diagnostic platforms including many cutting-edge technologies are utilized for the execution of transplant diagnostic procedures, including Histocompatibility testing, blood profiling, and genomic profiling. Since these technologies are combined with traditional PCR/NGS equipment, the price of these cutting-edge items is quite costly.
Research Methodology:
After secondary research provided a fundamental understanding of the worldwide Transplant Diagnostics Market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering Transplant Diagnostics Market details, as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered.
Transplant Diagnostics Market based on Product & Service:
- Instruments
- Reagents & Consumables
Transplant Diagnostics Market based on Screening Type:
- Pre-Transplant
- Post-Transplant
Transplant Diagnostics Market based on Organ Type:
- Kidney
- Liver
- Heart
- Lung
- Pancreas
Transplant Diagnostics Market based on Geography:
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific (RoAPAC)
- Latin America (LATAM)
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa (MEA)
- UAE
- Turkey
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
For the duration of the projected period, the transplant diagnostics market was dominated by the molecular assay technologies segment.
The market share that molecular assay technologies held in 2022 was the highest. At a CAGR of 8.0% over the course of the projection period, this segment is expected to grow from USD 4,166.0 in 2022 to USD 6,156.9 million in 2028. Donor-recipient compatibility testing in transplant diagnostic processes is accomplished through the use of molecular tests. The increased need for molecular tests in transplant diagnostic processes can be mostly related to the technological advantages they offer over non-molecular assays. These advantages include high procedural efficacy, the ability to analyze many samples, and real-time analysis.
In the transplant diagnostics market, independent reference laboratories are anticipated to grow at the quickest rate among end users throughout the projected timeframe.
With a market share of 58.65% in 2022, independent reference laboratories will have a higher proportion. From USD 2,668.8 in 2022 to USD 4,233.9 in 2028, this end-user category is expected to grow. Over the course of the projection period, this end-user category is anticipated to increase at the highest CAGR of 8.0%. This segment’s significant share can be ascribed to the growing number of research & development activities as well as the quick modernization and automation of diagnostic laboratories.
The Reagents & Consumables category holds the highest proportion of the transplant diagnostics market in terms of Product & Services. Reagents & Consumables will command the most share of the market in 2022—roughly 72.2%. It is anticipated that the Product & Service segment would grow from USD 3,265.2 million in 2022 to USD 5,131.0 million in 2028. The majority of transplant diagnostics are made up of reagents and consumables. expansion of the fields in which molecular test techniques can be applied in organ transplant diagnostics, with a growing focus on early and efficient patient profiling.
During the projection period, infectious disease testing held the greatest share of the transplant diagnostics market by application. It is predicted that the cost of testing for infectious diseases will increase from USD 2,344.0 million in 2022 to USD 3,764.3 million in 2028.This market is expanding at a high compound annual growth rate (CAGR) due to several factors, including the continuous technological advancements in the field of molecular assay techniques, the growing use of these techniques for pathogen detection and histocompatibility testing, and the increasing incidence of infectious chronic diseases.
Over the course of the forecast period, North America is anticipated to hold the top spot in the transplant diagnostics market. With a 45.4% market share in 2022, North America—which includes the US and Canada—held the highest proportion. A significant portion of North America is affected by factors like the high frequency of diseases, the growing elderly population, and the rise of infectious diseases. Organ donation rates are rising, and public and private reimbursement programs are among the reasons why the APAC area is expanding at the fastest rate—8.3%.
- This report illustrates the most vital attributes of the Transplant Diagnostics Market, which are driving and providing opportunities.
- This research gives an in-depth analysis of the Transplant Diagnostics Market growth on the basis of several segments in the market.
- This report presents the predictions of the past and present trends of the Transplant Diagnostics Market.
- This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Transplant Diagnostics Market.
List of Tables
TABLE 1. TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 2. TRANSPLANT DIAGNOSTICS MARKET VALUE FOR INSTRUMENTS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 3. TRANSPLANT DIAGNOSTICS MARKET VALUE FOR REAGENTS & CONSUMABLES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 5. TRANSPLANT DIAGNOSTICS MARKET VALUE FOR PRE-TRANSPLANT, 2021-2030 (USD BILLION)
TABLE 6. TRANSPLANT DIAGNOSTICS MARKET VALUE FOR POST-TRANSPLANT AND OROPHARYNGEAL SWABS, 2021-2030 (USD BILLION)
TABLE 7. TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 8. TRANSPLANT DIAGNOSTICS MARKET VALUE FOR KIDNEY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 9. TRANSPLANT DIAGNOSTICS MARKET VALUE FOR LIVER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. TRANSPLANT DIAGNOSTICS MARKET VALUE FOR HEART, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 11. TRANSPLANT DIAGNOSTICS MARKET VALUE FOR LUNG, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 12. TRANSPLANT DIAGNOSTICS MARKET VALUE FOR PANCREAS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 13. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 14. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 15. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 16. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 17. U.S TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 18. U.S TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 19. U.S TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 20. U.S TRANSPLANT DIAGNOSTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 21. CANADA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 22. CANADA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 23. CANADA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 24. MEXICO TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 25. MEXICO TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 26. MEXICO TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 27. EUROPE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 28. EUROPE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 29. EUROPE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 30. EUROPE TRANSPLANT DIAGNOSTICS MARKET VALUE, END USE INDUSTRIES, 2021-2030 (USD BILLION)
TABLE 31. GERMANY TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 32. GERMANY TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 33. GERMANY TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 34. U.K TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 35. U.K TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 36. U.K TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 37. FRANCE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 38. FRANCE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 39. FRANCE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 40. ITALY TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 41. ITALY TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 42. ITALY TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 43. SPAIN TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 44. SPAIN TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 45. SPAIN TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 46. ROE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 47. ROE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 48. ROE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 49. ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 50. ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 51. ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 52. ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 53. CHINA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 54. CHINA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 55. CHINA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 56. INDIA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 57. INDIA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 58. INDIA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 59. JAPAN TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 60. JAPAN TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 61. JAPAN TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 62. REST OF APAC TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 63. REST OF APAC TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 64. REST OF APAC TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 65. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 66. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 67. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 68. BRAZIL TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 69. BRAZIL TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 70. BRAZIL TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 71. ARGENTINA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 72. ARGENTINA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 73. ARGENTINA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 74. MIDDLE EAST AND AFRICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 75. MIDDLE EAST AND AFRICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 76. MIDDLE EAST AND AFRICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 77. SAUDI ARABIA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 78. SAUDI ARABIA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 79. SAUDI ARABIA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 80. UAE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 81. UAE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 82. UAE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 83. REST OF MIDDLE EAST AND AFRICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 84. REST OF MIDDLE EAST AND AFRICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 85. REST OF MIDDLE EAST AND AFRICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 86. HOLOGIC, INC. (U.S.): FINANCIALS
TABLE 87. HOLOGIC, INC. (U.S.): PRODUCTS & SERVICES
TABLE 88. HOLOGIC, INC. (U.S.): RECENT DEVELOPMENTS
TABLE 89. BIOFORTUNA LIMITED (U.K.): FINANCIALS
TABLE 90. BIOFORTUNA LIMITED (U.K.): PRODUCTS & SERVICES
TABLE 91. BIOFORTUNA LIMITED (U.K.): RECENT DEVELOPMENTS
TABLE 92. TAKARA BIO INC. (JAPAN): FINANCIALS
TABLE 93. TAKARA BIO INC. (JAPAN): PRODUCTS & SERVICES
TABLE 94. TAKARA BIO INC. (JAPAN): RECENT DEVELOPMENTS
TABLE 95. ABBOTT (U.S.): FINANCIALS
TABLE 96. ABBOTT (U.S.): PRODUCTS & SERVICES
TABLE 97. ABBOTT (U.S.): RECENT DEVELOPMENTS
TABLE 98. DIAGNÓSTICA LONGWOOD SL (SPAIN): FINANCIALS
TABLE 99. DIAGNÓSTICA LONGWOOD SL (SPAIN): PRODUCTS & SERVICES
TABLE 100. DIAGNÓSTICA LONGWOOD SL (SPAIN): RECENT DEVELOPMENTS
TABLE 101. ADAPTIVE BIOTECHNOLOGIES (U.S.): FINANCIALS
TABLE 102. ADAPTIVE BIOTECHNOLOGIES (U.S.): PRODUCTS & SERVICES
TABLE 103. ADAPTIVE BIOTECHNOLOGIES (U.S.): RECENT DEVELOPMENTS
TABLE 104. NANOSTRING TECHNOLOGIES, INC.(U.S.): FINANCIALS
TABLE 105. NANOSTRING TECHNOLOGIES, INC.(U.S.): PRODUCTS & SERVICES
TABLE 106. NANOSTRING TECHNOLOGIES, INC.(U.S.): DEVELOPMENTS
TABLE 107. ARQUER DIAGNOSTICS LTD (U.K.): FINANCIALS
TABLE 108. ARQUER DIAGNOSTICS LTD (U.K.): PRODUCTS & SERVICES
TABLE 109. ARQUER DIAGNOSTICS LTD (U.K.): RECENT DEVELOPMENTS
TABLE 110. F. ALTONA DIAGNOSTICS GMBH (GERMANY): FINANCIALS
TABLE 111. F. ALTONA DIAGNOSTICS GMBH (GERMANY): PRODUCTS & SERVICES
TABLE 112. F. ALTONA DIAGNOSTICS GMBH (GERMANY): RECENT DEVELOPMENTS
TABLE 113. ELITECHGROUP (FRANCE): FINANCIALS
TABLE 114. ELITECHGROUP (FRANCE): PRODUCTS & SERVICES
TABLE 115. ELITECHGROUP (FRANCE): RECENT DEVELOPMENTS
